Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B

(2014) Q. Xie et al.   CLINICAL INFECTIOUS DISEASES

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)

(2014) Qin Ning et al.   JOURNAL OF HEPATOLOGY

Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study

(2014) Yu-hua Liu et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Efficacy and safety of peginterferon alfa-2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B

(2013) Dong Jin Suh et al.   ANTIVIRAL THERAPY

Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B

(2013) Yun-Fan Liaw   HEPATOLOGY

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion

(2013) Zhen Huan Cao et al.   Journal of Digestive Diseases

Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study

(2013) Z. Huang et al.   JOURNAL OF VIRAL HEPATITIS

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes

(2013) L. Boglione et al.   JOURNAL OF VIRAL HEPATITIS

A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B

(2012) Paola Piccolo et al.   ANTIVIRAL THERAPY

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

(2012) Stephanos J. Hadziyannis et al.   GASTROENTEROLOGY

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

(2012) Pietro Lampertico et al.   GUT

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation

(2011) C.-C. Chen et al.   JOURNAL OF VIRAL HEPATITIS

Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?

(2010) V. Rijckborst et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

(2010) R. Moucari et al.   JOURNAL OF VIRAL HEPATITIS

A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B

(2009) Paola Piccolo et al.   ANTIVIRAL THERAPY

Hepatitis B Virus Resistance to Nucleos(t)ide Analogues

(2009) Fabien Zoulim et al.   GASTROENTEROLOGY

Control of cccDNA function in hepatitis B virus infection

(2009) Massimo Levrero et al.   JOURNAL OF HEPATOLOGY

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

(2008) Rami Moucari et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

(2008)   JOURNAL OF HEPATOLOGY